IMNM vs. VKTX, MTSR, SWTX, SRRK, MLTX, PTGX, AAPG, HCM, INDV, and APLS
Should you be buying Immunome stock or one of its competitors? The main competitors of Immunome include Viking Therapeutics (VKTX), Metsera (MTSR), SpringWorks Therapeutics (SWTX), Scholar Rock (SRRK), MoonLake Immunotherapeutics (MLTX), Protagonist Therapeutics (PTGX), Ascentage Pharma Group International (AAPG), HUTCHMED (HCM), Indivior (INDV), and Apellis Pharmaceuticals (APLS). These companies are all part of the "pharmaceutical products" industry.
Immunome vs. Its Competitors
Viking Therapeutics (NASDAQ:VKTX) and Immunome (NASDAQ:IMNM) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, media sentiment, profitability, institutional ownership, earnings and risk.
In the previous week, Immunome had 11 more articles in the media than Viking Therapeutics. MarketBeat recorded 20 mentions for Immunome and 9 mentions for Viking Therapeutics. Viking Therapeutics' average media sentiment score of 1.23 beat Immunome's score of 0.69 indicating that Viking Therapeutics is being referred to more favorably in the media.
Viking Therapeutics has a beta of 0.67, meaning that its share price is 33% less volatile than the S&P 500. Comparatively, Immunome has a beta of 1.93, meaning that its share price is 93% more volatile than the S&P 500.
Viking Therapeutics presently has a consensus target price of $86.92, indicating a potential upside of 117.14%. Immunome has a consensus target price of $23.14, indicating a potential upside of 125.13%. Given Immunome's higher probable upside, analysts plainly believe Immunome is more favorable than Viking Therapeutics.
Viking Therapeutics has higher earnings, but lower revenue than Immunome. Viking Therapeutics is trading at a lower price-to-earnings ratio than Immunome, indicating that it is currently the more affordable of the two stocks.
76.0% of Viking Therapeutics shares are owned by institutional investors. Comparatively, 44.6% of Immunome shares are owned by institutional investors. 4.1% of Viking Therapeutics shares are owned by insiders. Comparatively, 7.7% of Immunome shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Viking Therapeutics has a net margin of 0.00% compared to Immunome's net margin of -1,687.08%. Viking Therapeutics' return on equity of -19.98% beat Immunome's return on equity.
Summary
Viking Therapeutics beats Immunome on 9 of the 15 factors compared between the two stocks.
Get Immunome News Delivered to You Automatically
Sign up to receive the latest news and ratings for IMNM and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding IMNM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Immunome Competitors List
Related Companies and Tools
This page (NASDAQ:IMNM) was last updated on 8/16/2025 by MarketBeat.com Staff
MarketBeat All Access